Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 19, 2009 - Issue 7
Submit an article Journal homepage
759
Views
77
CrossRef citations to date
0
Altmetric
Reviews

Chemical penetration enhancers: a patent review

Abdul Ahad Faculty of Pharmacy Hamdard University, Department of Pharmaceutics 110 062, New Delhi, India +91 9811798725; +91 11 26059663; [email protected]
,
Mohammed Aqil Faculty of Pharmacy Hamdard University, Department of Pharmaceutics 110 062, New Delhi, India +91 9811798725; +91 11 26059663; [email protected]
,
Kanchan Kohli Faculty of Pharmacy Hamdard University, Department of Pharmaceutics 110 062, New Delhi, India +91 9811798725; +91 11 26059663; [email protected]
,
Hema Chaudhary Faculty of Pharmacy Hamdard University, Department of Pharmaceutics 110 062, New Delhi, India +91 9811798725; +91 11 26059663; [email protected]
,
Yasmin Sultana Faculty of Pharmacy Hamdard University, Department of Pharmaceutics 110 062, New Delhi, India +91 9811798725; +91 11 26059663; [email protected]
,
Mohammed Mujeeb Faculty of Pharmacy Hamdard University, Department of Pharmaceutics 110 062, New Delhi, India +91 9811798725; +91 11 26059663; [email protected]
&
Sushama Talegaonkar Faculty of Pharmacy Hamdard University, Department of Pharmaceutics 110 062, New Delhi, India +91 9811798725; +91 11 26059663; [email protected]
 show all
Pages 969-988 | Published online: 24 Jun 2009

Bibliography

  • Leonard RB, Matthias MT, Charles FB. Dermal penetration enhancer and drug delivery systems involving same. JP2007326867; 2007
  • Timothy MM, Nina WF, Katgryn KT, et al. Transdermal delivery rate control using amorphous pharmaceutical compositions. US2005175680; 2005
  • Amar L, Geena M. Transdermal pharmaceutical spray formulations comprising a vp/va copolymer and a non-aquous vehicle. US2007219171; 2007
  • Carlos S, Scott KF, Robert GJ. Non-steroidal antiinflammatory drug formulations for topical application to the skin. CA2299288; 1999
  • Schaefer H, Redelmeier TE. Structure and dynamics of the skin barrier. In: Schaefer H, Redelmeier TE, editors, Skin Barrier. Karger,Tokyo, Japan; 1996. p. 1-33
  • Asbill CS, Michniak BB. Percutaneous penetration enhancers: local versus transdermal activity. PSTT 2000;3:36-41
  • Kanikkannan N, Kandimalla K, Lamba SS, Singh M. Structure activity relationship of chemical penetration enhancers in transdermal drug delivery. Curr Med Chem 2000;7:593-608
  • Norberto RCD, Arnaud G, Celine B. Pharmaceutical compositions of nicotine and methods of use thereof. WO2008012071; 2008
  • Anant PK. A transdermal topical composition and its uses. CA2602018; 2006
  • Buyuktimkin N, Buyuktimkin S, Rytting JH. Chemical means of transdermal drug permeation enhancement. In: Ghosh TK, Pfister WR, Yum SI, editors, Transdermal and Topical Drug Delivery Systems, Interpharm Press, IL, 1997. p. 357-475
  • Barry BW. Dermatological formulations: percutaneous absorption, Marcel Dekker, New York; 1983
  • Shah VP. Skin penetration enhancers: scientific perspective. In: Hsieh DS, editor, Drug Permeation and Enhancement Marcel Dekker, New York, USA; 1994. p. 19-23
  • Smith EW, Maibach HI. Percutaneous penetration enhancers: the fundamentals. Chapter 1.1. In: Smith EW, Maibach HI, editors, Percutaneous Penetration Enhancers. CRC Press, Boca Raton; 1995. p. 1-4
  • Chattaraj SC, Walker RB. Chapter 2. In: Smith EW, Maibach HI, editors, Percutaneous Penetration Enhancers. CRC Press, Boca Raton1; 1995. p. 5-20
  • Alexander H, Pavel D, Oldrich FM, et al. Omega-amino acid derivatives, processes of their preparation and their use. US6187938; 2001
  • Goodman M, Barry BW. Lipid– protein partitioning theory (LPP) theory of skin enhancer activity: finite dose technique. Int J Pharm 1989;57:29-40
  • Chensheng L. Composition and methods for transdermal delivery of acid-labile drugs. MX9705070; 1998
  • Golden GM, McKie JE, Potts RO. Role of stratum corneum lipid fluidity in transdermal drug flux. J Pharm Sci l987;76:25-8
  • Angela AN, Samir R, Vesna A. Formulations and methods for enhancing the transdermal penetration of a drug. US2007065494; 2007
  • Chi SC, Park ES, Kim H. Effect of penetration enhancers on flurbiprofen permeation through rat skin. Int J Pharm 1995;126:267-74
  • Schroeder IZ, Franke P, Schaefer UF, Lehr CM. Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs. J Control Release 2007;118:196-203
  • Gao S, Singh J. Effect of oleic acid:ethanol and oleic acid:propylene glycol on the in vitro percutaneous absorption of 5-fluorouracil and tamoxifen and the macroscopic barrier property of porcine epidermis. Int J Pharm 1998;165:45-55
  • Cotte M, Dumas P, Besnard M, et al. Synchrotron FT-IR microscopic study of chemical enhancers in transdermal drug delivery: example of fatty acids. J Control Release 2004;97:269-81
  • Tanojo H, Boelsma E, Junginger HE, et al. In vivo human skin barrier modulation by topical application of fatty acids. Skin Pharm Appl Skin Phys 1998;11:87-97
  • Paraskevas D, Dimitrios R, Theodora G. Pharmaceutical composition for the systemic delivery of ketotifen through the skin. GR1004995; 2005
  • Chaim A, Oren C, Rami BO, et al. Pharmaceutical composition and method for transdermal drug delivery. US2005020552; 2005
  • Danyi Q, Ana R, Angela A. Norethindrone sustained release formulations and methods associated therewith. WO2005060540; 2005
  • Robert DE. Method for treating erectile dysfunction and increasing libido in men. CA2420895; 2002
  • Uday J, Charles ED, Srinivasan V. Drug delivery compositions for improved stability of steroids. MX9800545; 1998
  • Woong CJ, Deog SJ, Min PC. Transdermal composition of an antivomiting agent. WO2004054552; 2004
  • Carla GN, Matthias MT, Charles FB, Leonard RB. Topical cosmetic compositions for transdermal delivery. NZ537359; 2006
  • Srinivasan V, David F, Sonal P. Fatty acid esters of lactic acid salts as permeation enhancers. WO9818417; 1998
  • Franz-Josef B. Transdermal device for the delivery of alfuzosin. WO9630020; 1996
  • Thomas HD, Lothar D. Transdermal system per admin. of galanthamine – esp. for treatment of Alzheimer's disease and alcohol addiction. DE4301783; 1994
  • Nicholas B, Thorsteinn L. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol. US4983396; 1991
  • Nicholas B, Thorsteinn L. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol. US4885174; 1989
  • Lee FM, Owen PR. Transdermal flux enhancing pharmaceutical compositions containing 15-75% ethanol and penetration enhancer. NZ222346; 1990
  • Nicholas B, Thorsteinn L. Transdermal delivery system. CA1280974; 1991
  • Bruce A, Robert DC. Trandermal delivery of opioids. US4626539; 1986
  • Funke AP, Schiller R, Motzkus HW, et al. Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. Pharm Res 2002;19:661-68
  • Sinha VR, Kaur MP. Permeation enhancers for transdermal drug delivery. Drug Dev Ind Pharm 2000;26(11):1131-40
  • Okabe H, Obata Y, Takayama K, Nagai T. Percutaneous absorption enhancing effect and skin irritation of monocyclic monoterpenes. Drug Des Deliv 1990;6:229-38
  • Williams AC, Barry BW. Terpenes and the lipid protein partitioning theory of skin penetration enhancement. Pharm Res 1991;8:17-24
  • Lim PF, Liu XY, Kang L, et al. Physicochemical effects of terpenes on organogel for transdermal drug delivery. Int J Pharm 2008;358:102-7
  • Font AF, Fernandez CB, Merino V, et al. Effect of chemical enhancers on the in vitro percutaneous absorption of sumatriptan succinate. Eur J Pharm Biopharm 2005;61:50-5
  • Amnuaikit C, Ikeuchi I, Ogawara K, et al. Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use. Int J Pharm 2005;289:167-78
  • Ogiso T, Iwaki M, Paku T. Effect of various enhancers on transdermal penetration of indomethacin and urea, and relationship between penetration parameters and enhancement factors. J Pharm Sci 1995;84:482-88
  • Rizwan M, Aqil M, Ahad A, et al. Transdermal delivery of valsartan: I. Effect of various terpenes. Drug Dev Ind Pharm 2008;34:618-26
  • Sukhon L, Chin-Ming C, James C, Orest O. Transdermal drug delivery system. WO2008058220; 2008
  • Jain R, Aqil M, Ahad A, et al. Basil oil is a promising skin penetration enhancer for transdermal delivery of labetolol hydrochloride. Drug Dev Ind Pharm 2008;34(4):384-89
  • Norberto CDR, Arnaud G, Celine B, et al. Permeation enhancer comprising genus curcuma or germacrone for transdermal and topical administration of active agents. WO2005105059; 2005
  • Norberto CDR, Arnaud G, Celine B, et al. Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents. US2005244522; 2005
  • Lu MF, Hui H. Transdermal drug delivery composition. WO9008553; 1999
  • Deog SJ, Min PC, Kwon CY, et al. Transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, and the manufacturing method thereof. US6723337; 2004
  • Andega S, Kanikkannan N, Singh M. Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin. J Control Release 2001;77:17-25
  • Kanikkannan N, Singh M. Skin permeation enhancement effect and skin irritation of saturated fatty alcohols. Int J Pharm 2002;248:219-28
  • David KP, Juan MA. Compositions and methods for delivery of amino-functional drugs. US2007212410; 2007
  • David KP, Juan MA. Compositions and methods for delivery of amino-functional drugs. WO2007100757; 2007
  • Benjamin KK. Nitroglycerin transdermal delivery system. EP0224981; 1987
  • Santoyo S, Arellano A, Ygartua P, Martin C. Penetration enhancer effects on the in–vitro percutaneous absorption of piroxicam through rat skin. Int J Pharm 1995;117:219-24
  • Bhatt PP, Rytting JH, Topp EM. Influence of azone and lauryl alcohol on the transport of acetaminophen and ibuprofen through shed snake skin. Int J Pharm 1991;72:219-26
  • Turunen TM, Buyuktimkin S, Buyuktimkin N, et al. Enhancer delivery of 5-fluorouracil through shed snake skin by two transdermal penetration enhancers. Int J Pharm 1993;92:89-95
  • Itoh T, Wasinger L, Turunen TM, Rytting JH. Effects of transdermal penetration enhancers on the permeability of shed snake skin. Pharm Res 1992;9:1168-72
  • Barry BW, Southwell D, Woodford R. Optimization of bioavailability of topical steroids: penetration enhancers under occlusion. J Invest Dermatol 1984;82:49-52
  • Priborsky J, Takayama K, Nagai T, et al. Comparison of penetration-enhancing ability of laurocapram, N-methyl-2-pyrrolidone and dodecyl-L-pyroglutamate. Pharm Weekbl Sci 1988;10(5):189-92
  • Akhter SA, Barry BW. Absorption through human skin of ibuprofen and flurbuprofen: effect of dose variation, deposited drug films, occlusion and the penetration enhancer N-methyl-2-pyrrolidone. J Pharm Pharmacol 1985;37:27-37
  • Kim DD, Chien YW. Transdermal delivery of zalcitabine (DDC): in vitro skin permeation study. AIDS 1995;9:1331-36
  • Kim DD, Chien YW. Transdermal delivery of dideoxynucleosidetype anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J Pharm Sci 1996;85:214-19
  • Sharad GK, Edward RM, Dale SG. Transdermal nitroglycerin patch with penetration enhancers. US5262165; 1993
  • Sharad GK, Edward RM, Dale SG. Transdermal nitroglycerin patch with penetration enhancers. EP0417496; 1991
  • Babu RJ, Dhanasekaran M, Vaithiyalingam SR, et al. Cardiovascular effects of transdermally delivered bupranolol in rabbits: effect of chemical penetration enhancers. Life Sci 2008;82:273-8
  • Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-18
  • Barry BW. Mode of action of penetration enhancers in human skin. J Control Release 1987;6:85-97
  • Anigbogu ANC, Williams AC, Barry BW, Edwards HGM. Fourier transform Raman spectroscopy of interactions between the penetration enhancer dimethylsulphoxide and human stratum corneum. Int J Pharm 1995;125:265-82
  • Smith EW, Maibach HI. In: Smith EW, Maibach HI, editors, Percutaneous Penetration Enhancers, CRC Press, New York; 1995. p. 1-4
  • Embery G, Dugrad PH. The isolation of DMSO soluble components from human epidermis preparations: a possible mechanism of action of dimethylsulfoxidc in affecting percutaneous migration phenomena. J Invest Dermatol 1971;57:308-31
  • Carpentieri-Rodrigues LN, Zanluchi JM, Hinke I. Percutaneous absorption enhancers: mechanisms and potential. Brazil Arch Bio Tech 2007;50:949-61
  • Clancy MJ, Corish J, Corrigan OI. A comparison of (the effects of electrical current and penetration enhancers on the properties of human skin using spectroscopic (FTIR) and calorimetric (DSC) methods. Int J Pharm 1994;105:47-56
  • Xu GQ, Xi NZ, Chen GS, et al. Effect of enhancers on cutaneous permeation of piroxicam in vitro. Chung Kuo Yao Li Hsueh Pao 1991;12(3):235-38
  • David RM, George DR. Topical preparation and method for transdermal delivery and localization of therapeutic agents. WO2005120407; 2005
  • Doron F, Joseph S, Haim A. Topical and transdermal delivery system utilizing submicron oil spheres. WO9318752; 1993
  • Doron F, Joseph S, Haim A. Topical and transdermal delivery system utilizing submicron oil spheres. US6113921; 2000
  • Cornwell PA, Barry BW. The effects of a series of homologous terpene alcohols on the lipid structure of human stratum corneum as assessed by differential scanning calorimetry. In: Scott RC, Guy RH, Hadgraft J, Bodd HEC, editors, Prediction of Percutaneous Absorption. Vol. 2. IBC Technical Services. London; 1992. p. 394-400
  • Parikh DK, Ghosh TK. Feasibility of transdermal delivery of fluoxetine. AAPS PharmSciTech 2005;6(2):E114-49
  • Tenjarla SN, Holbrook JH, Pvranajoti P, et al. Evaluating the irritation potential of skin penetration enhancers in the hairless guinea pig. Cutan Ocul Toxicol 1995;14:299-307
  • Goodman M, Barry BW. Action of penetration enhancers on human skin as assessed by the permeation of model drugs 5-fluorouracil and estradiol. J Invest Dermatol 1988;91:323-27
  • Owen PR, Lee FM. Transdermal flux enhancing compositions. EP0331382; 1989
  • Michael FL, Russell PO. Transdermal flux enhancing compositions to treat hypertension, diabetes and angina pectoris. US5391548; 1995
  • Ruland A, Kreuter J. Influence of various penetration enhancers on the in vitro permeation of amino acids across hairless mouse skin. Int J Pharm 1992;85:7-17
  • Gevork M, James PV. Penetration enhancers for transdermal delivery of systemic agents. US4886783; 1989
  • Igor G, Matthias MT, Frances WN, et al. Method and system for rapid transdermal administration. MXPA06006041; 2007
  • Vithal RJ. Penetration enhancers for transdermal drug delivery of systemic agents. US4562075; 1985
  • Vithal RJ. Improved penetration enhancers for transdermal drug delivery of systemic agents. EP0095169; 1983
  • Vithal RJ. Penetration enhancers for transdermal drug delivery of systemic agents. US4405616; 1983
  • Gevork M, James VP, Eric LN. Penetration enhancers for transdermal delivery of systemic agents. US5270346; 1993
  • Stoughton RB. Azone (l-dodecylazacycloheptan-2-one) enhances percutaneous penetration. In: Farber EM, editor, Psoriasis, Grune and Stratton. Orlando, FL; 1982. p. 346-98
  • Turkoglu M, Sakr A. Evaulation of irritation potential of surfactant mixtures. Int J Cos Sci 2001;21:371-82
  • Ribaud C, Garson J, Doucet J, Leveque J. Organization of stratum corneum lipids in relation to permeability: Influence of sodium lauryl sulphate and preheating. Pharm Res IL 1994;11(10):1414-18
  • Samir M, Pankaj KS, Amit JK. Penetration enhancer combinations for transdermal delivery. US2007269379; 2007
  • Kimu BK. Article for percutaneous medication of estradiol. JP2003607; 1990
  • Kim CK, Kim JJ, Chi SC, Shim CK. Effect of fatty acids and urea on the penetration of ketoprofen through rat skin. Int J Pharm 1993;99:109-18
  • Chaim A, Oren C, Rami BO, et al. Pharmaceutical composition and method for transdermal drug delivery. US2005042268; 2005
  • Naohisa K, Ken-Ichi NG, Junji K, et al. Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer. WO2004026313; 2004
  • George EKF. Topical application of muscarinic analgesic drugs such as neostigmine. US6011022; 2000
  • George EKF. Topical application of muscarinic analgesic drugs such as neostigmine. WO0135927; 2001
  • George EK. Topical application of muscarinic analgesic drugs such as neostigmine. TW265027B; 2006
  • George EKF. Topical application of opioid analgesic drugs such as morphine. US6143278; 2000
  • Okumura M, Nakamori Y, Sugibayashi K, Morimoto Y. Enhanced skin permeation of papaverine by a medium chain glyceride. Drug Des Deliv 1991;7:147-57
  • Ben-Shabat S, Baruch N, Sintov AC. Conjugates of unsaturated fatty acids with propylene glycol as potentially less-irritant skin penetration enhancers. Drug Dev Ind Pharm 2007;33:1169-75
  • Ju KJ, Hyun BW, Chul LY, Gyu CY. Medicinal patches for percutaneous administration. WO9619976; 1996
  • Danyi Q, Ninad D, Srinivasan V, Charles ED. Triacetin as a transdermal penetration enhancer. MX9707868; 1997
  • Dong-son M, Kee-an U, Yong-soo K, et al. Transdermal delivery matrix for piroxicam. US5916587; 1999
  • Mura P, Faucci MT, Bramanti G, Corti P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci 2000;9(4):365-72
  • Gene J, Norberto CD, Arnaud G. Pharmaceutical compositions of ropinirole and methods of use thereof. WO2008005240; 2008
  • Montague SC, Biljana T, Louis SD. Transdermal drug delivery systems. US2005287195; 2005
  • Chaim A, Oren C, Rami BO, et al. Pharmaceutical composition and method for transdermal drug delivery. US2005025833; 2005
  • David F, Charles ED, Srinivasan V, Lawrence NR. Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same. US2003091620; 2003
  • James YL. Topical compositions for prostaglandin E1. MXPA01011560; 2002
  • Nadir B, James YL, Servet B. Topical compositions for prostaglandin E1 delivery. CA2442479; 2000
  • Gevork M, James PV. Penetration enhancers for transdermal delivery of systemic agents. US5118676; 1992
  • James PV. Penetration enhances for transdermal delivery of systemic agents. US5118692; 1992
  • Nina W, Tony DP, Monique R, et al. Method and composition for transdermal drug delivery. CA2610708; 2006
  • Chin KH, Jeong YH. Hydrogel composition for transdermal drug delivery. NZ522532; 2005
  • Seung BJ, Ung CJ, Han LH. Pharmaceutical composition for treatment of erectile dysfunction and device for transdermal administration of formulation. KR100287626B; 2001
  • Chien YW, Xu H, Chiang CC, Hung YC. Transdermal controlled administration of indomethacin: I. Enhancement of skin permeability. Pharm Res 1988;5:103-6
  • Porzio S, Caselli G, Pellegrini L, et al. Efficacy of a new topical gel-spray formulation of ketoprofen lysine salt in the rat: percutaneous permeation in vitro and in vivo and pharmacological activity. Pharmacol Res 1998;37:41-7
  • Friend D, Catz P, Heller J, et al. Transdermal delivery of levonorgestrel I. Alkanols as permeation enhancers. J Control Release 1988;7:243-50
  • Pershing LK, Lambert LD, Knutson K. Mechanism of ethanol-enhanced estradiol permeation across human skin in vivo. Pharm Res 1990;7:170-75
  • Friend D, Catz P, Hellcr J, et al. Simple alkyl esters as skin permeation enhancers. J Control Release l989;9:33-41
  • Sato K, Sugibayashi K, Morimoto Y. Effect and mode of action of aliphatic esters on in vitro skin permeation of nicorandil. Int J Pharm 1988;43:31-40
  • Hori M, Satoh S, Maibach HI, Guy RH. Enhancement of propranolol hydrochloride and diazepam skin absorption in vitro: effect of enhancer lipophilicity. J Pharm Sci 1991;80:32-35
  • Melendres JL, Nangia A, Sedik A, et al. Nonane enhances propranolol hydrochloride penetration in human skin. Int J Pharm 1993;92:243-48
  • Rizwan M, Azeem A, Aqil A, et al. Enhanced transdermal drug delivery techniques: an extensive review of patents. Rec Patents Drug Deliv Form 2009;3: (Article in press)
  • Aqil M, Ahad A, Sultana Y, Ali A. Status of terpenes as skin penetration enhancers. Drug Discov Today 2007;12:1061-67

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.